Skip to content

Study · Non-randomized trial · n = 11 · 2000

2 results

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.

Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB

Clinical endocrinology1 Dec 2000Cited by 36 (Europe PMC)

PMID11155094 (opens in a new tab)DOI10.1046/j.1365-2265.2000.01168.x (opens in a new tab)PepBankPUB-11155094
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly, lanreotide achieved GH < 5 mU/l in five (45%), four (36%), and three (27%) patients at 10, 14, and 21 days after the last injection.

    In plain wordsIn acromegaly, lanreotide achieved the GH target in five, four, and three patients at successive assessments.

    Peptide
    Lanreotide
    Outcome
    Not applicableGH below 5 mU/l after last injection
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · five injections at 14 day intervalsAs given in this study (human).

    Measurements

    Patients with GH < 5 mU/l
    45%
    10 days after last injection
    Patients with GH < 5 mU/l
    36%
    14 days after last injection
    Patients with GH < 5 mU/l
    27%
    21 days after last injection
    Patients with GH < 5 mU/l
    5 patients
    10 days after last injection
    Patients with GH < 5 mU/l
    4 patients
    14 days after last injection
    Patients with GH < 5 mU/l
    3 patients
    21 days after last injection

    Source sentences

    Summary
    In the lanreotide-treated group, five (45%), four (36%) and three (27%) patients, respectively, had a GH < 5 mU/l at 10, 14 and 21 days after the last injection
    1 context sentence
    Summary · context
    Twenty-seven patients with acromegaly were randomly allocated to receive either three injections at 4 week intervals of octreotide LAR (n = 18) or five injections at 14 day intervals of lanreotide (n = 11); two patients participated in both arms.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly, eight, six, and five lanreotide patients had normal IGF-I at 10, 14, and 21 days after the last injection.

    In plain wordsIn acromegaly, eight, six, and five lanreotide patients had normal IGF-I at successive assessments.

    Peptide
    Lanreotide
    Outcome
    Not applicableNormal serum IGF-I after last injection
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · five injections at 14 day intervalsAs given in this study (human).

    Measurements

    Patients with normal serum IGF-I
    8 patients
    10 days after last injection
    Patients with normal serum IGF-I
    6 patients
    14 days after last injection
    Patients with normal serum IGF-I
    5 patients
    21 days after last injection

    Source sentences

    Summary
    In the lanreotide-treated group, five (45%), four (36%) and three (27%) patients, respectively, had a GH < 5 mU/l at 10, 14 and 21 days after the last injection and eight, six and five patients had a normal serum IGF-I.
    1 context sentence
    Summary · context
    Twenty-seven patients with acromegaly were randomly allocated to receive either three injections at 4 week intervals of octreotide LAR (n = 18) or five injections at 14 day intervals of lanreotide (n = 11); two patients participated in both arms.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.